Yttrium-86 (Y-86) is a positron-emitting radionuclide with a 14.7-hour half-life that serves as an isotopically matched surrogate for Y-90, enabling quantitative PET imaging and personalized dosimetry ahead of targeted radionuclide therapy. Protheragen provides end-to-end Y-86 radiolabeling expertise—from vector design and chelator selection to GMP-compliant production—accelerating your radiopharmaceutical pipeline from early discovery through clinical translation.
Yttrium-86 is a transition metal radionuclide produced primarily via the 86Sr(p,n)86Y nuclear reaction using medical cyclotrons. With a physical half-life of 14.74 hours and 33% positron emission accompanied by high-energy gamma rays, Y-86 occupies a unique position in the radionuclide spectrum for PET imaging of intermediate-to-slow pharmacokinetic vectors. Its chemical identity to Y-90—both exist as Y3+ cations with identical coordination preferences—makes Y-86 the gold-standard imaging surrogate for predicting the biodistribution, pharmacokinetics, and absorbed dose of Y-90-labeled therapeutics.
Fig 1. Long-term Cherenkov luminescence imaging of mice injected with (A) 90Y-DTPA-IgG and (B) 90Y-DTPA-ALT836. (Ferreira, Carolina A., et al., 2020)
The radiochemistry of Y-86 centers on stable chelation with polyaminopolycarboxylate ligands. DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) remains the most widely adopted macrocyclic chelator, offering octadentate coordination that ensures exceptional kinetic inertness in vivo. CHX-A''-DTPA and its derivatives provide acyclic alternatives with rapid room-temperature labeling kinetics, while next-generation ligands such as H4octapa and 5p-C-NETA are emerging to address the kinetic limitations of conventional frameworks. These chelators are conjugated to targeting vectors—peptides, monoclonal antibodies, antibody fragments, or small molecules—via bifunctional coupling chemistry, enabling selective delivery to somatostatin receptors, HER2, EGFR, VEGF, and other oncological targets.
The concept of theranostics—integrating diagnostic imaging with targeted therapy using chemically matched radionuclide pairs—has fundamentally reshaped precision oncology. In this paradigm, a positron-emitting isotope visualizes target expression and quantifies biodistribution, while its therapeutic counterpart delivers cytotoxic radiation to the same molecular target. The Y-86/Y-90 pair exemplifies this approach: both isotopes exhibit identical coordination chemistry, ensuring that imaging data from Y-86 PET directly predicts the in vivo behavior of Y-90 therapeutics. This eliminates the dosimetric uncertainties associated with non-matched surrogates such as 111In, which has been shown to underestimate liver dose and overestimate renal and splenic exposure relative to Y-90 compounds.
Beyond the Y-86/Y-90 dyad, the theranostic landscape now encompasses multiple isotope combinations spanning beta and alpha emitters. The table below summarizes key matched pairs, their clinical applications, and the unique advantages driving their adoption across oncology and beyond.
| Matched Pair | Imaging Isotope (Role) | Therapeutic Isotope (Role) | Primary Clinical Applications |
|---|---|---|---|
| Y-86 / Y-90 | Y-86: PET imaging, dosimetry (14.7 h half-life, 33% β+) | Y-90: Pure β− therapy (64.1 h half-life) | Neuroendocrine tumors, lymphoma, solid tumors via peptides and antibodies |
| Ga-68 / Lu-177 | Ga-68: PET imaging (67.7 min half-life) | Lu-177: β− therapy with γ emission for imaging (6.7 d half-life) | PSMA-targeted prostate cancer, DOTA-peptide PRRT |
| I-124 / I-131 | I-124: PET imaging (4.2 d half-life) | I-131: β− therapy (8.0 d half-life) | Thyroid cancer, neuroblastoma, MIBG-avid tumors |
| Zr-89 / — | Zr-89: Long-half-life PET (78.4 h) | Often paired with Y-90 or Lu-177 therapeutics | Immuno-PET for antibody-based therapies, checkpoint inhibitor imaging |
| Cu-64 / Cu-67 | Cu-64: PET imaging (12.7 h half-life) | Cu-67: β− therapy (61.8 h half-life) | Peptide receptor imaging, antibody fragments, hypoxia targeting |
| Sc-44 / Sc-47 | Sc-44: PET imaging (3.97 h half-life) | Sc-47: β− therapy (3.35 d half-life) | Emerging pair for DOTA-based vectors with favorable dosimetry |
Protheragen operates as a fully integrated Radiopharmaceutical CRDMO and CRO, bridging the gap between radiochemical innovation and clinical application. Our Y-86 radiolabeling service is designed to support the full development continuum—from preclinical proof-of-concept studies and in vitro stability assessments to first-in-human IIT clinical trials. Whether your program requires DOTA-conjugated peptides for neuroendocrine tumor imaging, CHX-A''-DTPA-modified antibodies for immuno-PET, or novel chelator-vector constructs for next-generation theranostics, our multidisciplinary team of radiochemists, nuclear pharmacists, and regulatory specialists ensures seamless execution with uncompromising quality.
Each Y-86 radiolabeling project at Protheragen follows a structured, milestone-driven workflow that balances scientific rigor with operational efficiency. From initial vector assessment to final batch release, our process ensures full traceability, reproducibility, and compliance at every stage.
1. Project Consultation & Feasibility Assessment: We evaluate your targeting vector, chelator compatibility, and intended application to define technical requirements, timelines, and success criteria.
2. Vector Modification & Conjugation: The targeting molecule is functionalized with the selected bifunctional chelator under controlled stoichiometry, followed by purification and characterization of the bioconjugate.
3. Y-86 Radiometallation: The chelator-vector conjugate is incubated with Y-86 chloride in optimized buffer conditions, with reaction parameters fine-tuned to maximize radiochemical yield and specific activity.
4. Purification & Formulation: The radiolabeled product is purified using size-exclusion chromatography or solid-phase extraction, then formulated in a clinically compatible buffer for downstream use.
5. Quality Control & Release Testing: Comprehensive analytical testing confirms radiochemical purity, pH, osmolality, and sterility, with all results documented in a batch release record.
6. Preclinical or Clinical Deployment: The qualified Y-86 radiopharmaceutical is dispatched for in vivo imaging, biodistribution studies, or clinical administration with full chain-of-custody documentation.
Ready to advance your radiopharmaceutical program with precision Y-86 radiolabeling? Contact us today to discuss your project requirements, explore customized solutions, and receive a detailed proposal tailored to your therapeutic area and development stage. Our team is prepared to support your journey from initial vector design through clinical imaging and dosimetry—reach out to us and let Protheragen be your trusted partner in theranostic innovation.
Reference